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SUMMARY. A reversed-phase high-performance liquid chromatographic (RP-HPLC) method for related
substances test of seratrodast in bulk drugs has been developed. The separation was achieved on a
ZirChrom Kromasil C18 (200 mm×4.6 mm, 5 μm) column thermostated at 30 ºC using acetonitrile-0.05 M
pH 3.0 potassium dihydrogen orthophosphate buffer (60:40, v/v) as a mobile phase. Wavelength was set at
267 nm. An external standard method using a dilution of the sample solution as reference was used for the
purity test. The method was found to be simple, rapid, specific and sensitive with detection limit of 0.67 ng.
A thorough study has been undertaken to identify and characterize an unknown impurity at a level over
the identification threshold of 0.1 %, and its structure was elucidated as 7-(3,5,6-trimethyl-1,4-benzo-
quinone-2-yl)-7-p-tolyl-heptanoic acid based on the data of MS, UV, IR and NMR spectra. Formation of
the unknown impurity as well as the countermeasure was also discussed.
